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Oncogene activation during tumour development leads to changes in the
DNA replication programme that enhance DNA replication stress. Certain
regions of the human genome, such as common fragile sites and telomeres,
are particularly sensitive to DNA replication stress due to their inherently
‘difficult-to-replicate’ nature. Indeed, it appears that these regions sometimes
fail to complete DNA replication within the period of interphase when cells
are exposed to DNA replication stress. Under these conditions, cells use a
salvage pathway, termed ‘mitoticDNA repair synthesis (MiDAS)’, to complete
DNA synthesis in the early stages of mitosis. If MiDAS fails, the ensuing mito-
tic errors threaten genome integrity and cell viability. Recent studies have
provided an insight into howMiDAShelps cells to counteract DNA replication
stress. However, our understanding of the molecular mechanisms and regu-
lation of MiDAS remain poorly defined. Here, we provide an overview of
how DNA replication stress triggers MiDAS, with an emphasis on how
common fragile sites and telomeres are maintained. Furthermore, we discuss
how a better understanding of MiDAS might reveal novel strategies to target
cancer cells that maintain viability in the face of chronic oncogene-induced
DNA replication stress.1. Introduction
Genome instability is a defining hallmark of cancer [1] and is thought to promote
tumorigenesis in pre-cancerous lesions, aswell as karyotypic diversity (and hence
cellular heterogeneity) during cancer progression [2–4]. There are a number of
hypotheses for why tumour cells exhibit intrinsic genomic instability. These can
be broadly classified into two categories: those that posit a requirement for geno-
mic instability in the tumorigenesis process, and those that propose instability is
merely a by-product of other genetic changes that occur during tumorigenesis.
With respect to the latter, it is clear that loss of tumour suppressor gene function
often disrupts genome maintenance pathways. Genome instability in cancer is
also induced by the activation of oncogenes. The ability of oncogenes to induce
cell cycle entry and cell proliferation is well established. However, another conse-
quence of oncogene activation, and the one of most relevance to the subject of this
article, is the induction of chronic ‘DNA replication stress’. This term refers to any
condition that leads to the slowing and/or stalling of replication forks. Chronic
DNA replication stress has now been observed in a wide range of tumours and,
as a consequence, has been proposed as an additional hallmark of cancer [5,6].
Activation of oncogenes in the early stages of tumorigenesis leads to activation
of replication, double-strand break (DSB) formation, and a DNA damage
response. In turn, the induction of a DNA damage response results in senescence
or apoptosis in normal cells, which acts as a barrier to tumour formation. Cancer
cells, on the other hand, prevent senescence orapoptosis by inactivation of tumour
suppressor proteins, such as p53, and can thus tolerate much higher levels of
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2chronic DNA replication stress [5,7,8]. Although oncogenes
have been shown to increase replication origin firing and
depletion of nucleotide pools, increasing evidence points
towards replication–transcription collisions as the underlying
cause of oncogene-induced DNA replication stress [9–13].
A recent genome-wide mapping study of the DNA replica-
tion and transcription sites provided further insight into the
mechanism of transcription–replication conflicts induced by
oncogenes [12]. Over-expression of oncogenes was shown to
induce premature entry into S-phase from G1, and the acti-
vation of new replication origins located within highly
transcribed regions. This origin activation within protein-
coding genes led to replication fork collapse, DSB formation
and chromosomal translocations [12,14,15].
Given the prevalence of DNA replication stress in
tumorigenesis, it is imperative to understand the defence
mechanisms that cancer cells use to tolerate this stress. This
would afford us a potential opportunity to target a cancer
cell-specific vulnerability. One such defence mechanism that
was described recently in our laboratory is the activation of
an atypical type of DNA synthesis that occurs in the early
stages of mitosis [16]. This process, which we have termed
MiDAS (for mitotic DNA synthesis), appears to be a form of
homologous recombination-based DNA repair. MiDAS is
more prevalent in aneuploid cancer cells (or otherwise trans-
formed cells), where it counteracts DNA replication stress
that arises at ‘difficult-to-replicate’ loci. In this article, we
review the underlyingmechanisms that are believed to prevent
these loci from being duplicated in a timely manner. Further-
more, we discuss how MiDAS serves as a salvage pathway
to ensure completion of genome-wide replication and hence
prevent pathological chromosome mis-segregation events.2. Difficult-to-replicate loci—or the
‘enemies within’ the genome
There are certain regions in the human genome that are inher-
ently difficult to replicate. The best characterized examples are
the ribosomal DNA (rDNA), chromosome fragile sites and
telomeres [17]. These regions share at least some of the follow-
ing features: they contain repetitive and/or G-rich sequences,
which tend to formDNA secondary structures; they are associ-
ated with tightly bound protein complexes; they harbour
unusually long genes or highly transcribed regions that
increase the likelihood of collisions between the transcription
and replication machineries; they are packaged into hetero-
chromatin. Any or all of these features pose challenges to the
replication machinery that might impede replication fork pro-
gression [18,19]. Moreover, these regions frequently give rise
to ultra-fine anaphase bridges (UFBs), which connect the
separating sister masses of DNA during the anaphase of
mitosis. UFBs cannot be visualized using conventional DNA
dyes, and are detectable by immuno-staining for certain pro-
teins that coat the UFB, such as BLM and PICH [20]. In the
following sections, we review the key similarities and differ-
ences between the DNA replication characteristics of these
‘difficult-to-replicate’ regions.
2.1. rDNA
The rDNA consists of tandem repeats of DNAunits that encode
the rRNA required for protein translation. The rDNA poses achallenge for the replication machinery because it is so highly
transcribed, and hence DNA replication–transcription conflicts
are inevitable. rDNA loci require specialized proteins/mechan-
isms to maintain the stability of each individual rDNA unit
[21,22]. The high levels of transcription at the rDNA need to
be coordinated with DNA replication in order to prevent the
transcription and replication machineries from colliding. This
process is orchestrated by a dedicated replication fork barrier
positioned within each rDNA unit. Such barriers have been
characterized extensively in yeast, but also have been shown
to play an important role in human cells [17,23]. Despite the
presence of the replication fork barrier, the rDNA array in
yeast frequently segregates late in mitosis, probably due to
the late completion of replication at that site. The rDNA is
also prone to generate RNA : DNA hybrids (R-loops), in
which the RNA transcript base pairs with the DNA template
and displaces the complementary DNA strand. If not removed
in a timely manner, R-loops can disrupt the function of
underlying genes, and pathological R-loops are generally
associated with loci where replication–transcription collisions
are prevalent. As a consequence, the rDNA is a hotspot for
transcription-driven mutagenesis/recombination [24–29].
2.2. Fragile sites
Fragile sites are regions of the genome that are prone to form
visible gaps and breaks onmetaphase chromosomes following
perturbation of DNA synthesis. Fragile sites are categorized as
being either ‘common’ or ‘rare’ according to their prevalence in
the general population. Rare fragile sites are seen only in a
small percentage of the population and are caused by patho-
logical expansion of trinucleotide repeat sequences. Common
fragile sites (CFSs), by contrast, exist in all individuals
(reviewed in [30]). CFSs are frequently associated with the
breakpoints of genomic rearrangements in cancer cells, as
well as with micro-deletions and copy number variations
(reviewed in [31,32]). Several mechanisms have been proposed
to explain the sensitivity of CFSs to DNA replication stress,
although the precise underlying cause of fragility may vary
between different CFSs. However, CFSs are widely regarded
as being the last regions of the human genome to be replicated
[33]. CFSs tend to have an AT-rich sequence composition,
which can lead to the formation of DNA secondary structures
that can impede replisomemovement. Coupledwith their gen-
eral lack of active/dormant replication origins, this might
potentiate DNA replication stress during S-phase. However,
perhaps the most striking feature of CFSs is their propensity
to harbour large, actively transcribed genes that take at least
one full cell cycle to transcribe. As a consequence of this, a col-
lision between the replication and transcriptionmachineries on
the same template is inevitable. These collisions may generate
DNA damage and/or lead to the formation of pathological
R-loops [34–37].
The formation of breaks and gaps at CFSs on metaphase
chromosomes is often referred to as fragile site ‘expression’
[32,38,39]. The differential cell/tissue specificity of CFS
expression most likely reflects differences in the intrinsic tran-
scription and replication profiles in the different cell types,
but could also reflect an altered density of active replication ori-
gins (such as would be generated as a result of oncogene
activation; see above) or chromatin structure (such as by his-
tone hypo-acetylation) in different cell types [40–44]. The
most common way to induce CFS expression in cultured cells
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3is to expose them to the replicative DNA polymerase inhibitor
aphidicolin [45]. Interestingly, this can induce micro-deletions
at CFSs, a phenomenon similar to that seen in primary human
tumours [46]. Activation of oncogenes, which occurs during
cancer development, can also induce CFS expression [44],
and recurrent deletions in cancer have been mapped to CFSs
[44,47]. The most frequently expressed and best-characterized
CFSs in the human genome are FRA3B and FRA16D, which
harbour the tumour suppressor genes FHIT and WWOX,
respectively [34,45,48,49].
CFSs are conserved throughmammalian evolution, despite
their propensity to induce genomic instability [30]. The reason
for this high level of conservation is not known. Several expla-
nations have been proposed. First, in addition to defined gene
products, these loci encode crucial regulatory noncoding
sequences, such as miRNAs [50]. Second, CFSs may act as a
‘sensor’ for alerting the cell to a failure to complete replication
of the genome. If true, it seems likely that this function must be
overwhelmed in situations where the cell encounters high
levels of DNA replication stress, such as during oncogene-
induced tumorigenesis [16,30]. Another speculative role for
CFSs is that they serve to alert cells to the presence of invading
organisms such as viruses that generate DNA replication stress
as they seek to subvert the DNA synthesis machinery of the
host in order to propagate themselves.
Several DNA repair/DNA damage response proteins
have been implicated in CFS maintenance, including the
Fanconi anaemia protein FANCD2, the main checkpoint
kinase during replication stress ATR, the RAD51 recombinase,
the BLM helicase, the DNA structure-specific endonuclease,
MUS81, and the non-catalytic subunit of the XPF endonuclease,
ERCC1 [20,30,51–55]. For background reading on DNA
damage response proteins, we refer readers to the following
reviews [56,57]. Among these proteins, FANCD2 is frequently
used as a surrogate marker of the location of CFSs in human
cell nuclei [20]. Why this protein localizes to CFSs in this way
is still debated, but one possible explanation is that it associates
with R-loops generated at CFSs and elsewhere in the genome
[58–61]. For further details on the proteins required to promote
CFS stability, we refer readers to the following articles [31,62].
2.3. Telomeres
Telomeres are the specialized nucleoprotein structures that pro-
tect the natural ends of linear eukaryotic chromosomes from
being recognized as DSBs. Because of this, the chromosome
end is prevented from triggering either aDNAdamage response
or a chromosome end-to-end fusion [63]. Mammalian telomeres
are composed of TTAGGG repeats bound by a six-protein com-
plex called shelterin. The G-rich 30 terminating strand forms a
ssDNA overhang that is also necessary for telomere mainten-
ance because it can invade into the double-stranded telomeric
DNA to form a protective structure called the t-loop [64,65].
The shelterin complex is composed of dsDNA-associated
factors, TRF1 and TRF2, and the ssDNA overhang-binding
protein, POT1, togetherwith the TIN2, TPP1 and RAP1 proteins
(reviewed in [66,67]). Despite their constitutive heterochromatic
nature, telomeres can be transcribed by RNApolymerase II into
a long noncoding RNA called TERRA [68].
The unique structural and functional features of telomeres
promote chromosome stability. However, these features also
create challenges for the DNA replication machinery, and
telomeres are intrinsically difficult to replicate. For example,replication fork progression can be impeded by one or
more of the following: (i) G-rich repetitive sequences that
form DNA secondary structures such as G-quadruplexes;
(ii) the tightly bound shelterin complex, which can form a
physical blockade to the replisome; (iii) the t-loop, which
can inhibit replication fork progression if not appropriately dis-
mantled and (iv) the formation of TERRA-associated R-loops.
Another feature of telomeric replication is that it is uni-
directional. This might contribute to the difficult-to-replicate
nature of each telomere because there are no available ‘down-
stream’ replication origins that can be activated in the event
of prolonged or irreparable replication fork stalling [69,70].
Telomeres have been shown to phenotypically resemble
fragile sites, in that they exhibit overt fragility under replica-
tion stress conditions [71]. Because telomeric fragility is
technically challenging to detect, the use of telomeric fluor-
escence in situ hybridization-based staining is widespread.
Fragility at telomeres is generally defined as the presence of
either multi-telomeric signals or elongated telomeres. Similar
to CFSs, low dose aphidicolin treatment induces telomere fra-
gility. A number of factors suppress this fragility, including
telomere-associated proteins, such as TRF1, as well as two
DNA helicases, BLM and RTEL1, which are recruited to telo-
meres during S-phase [71–74]. Two recent reviews provide a
more comprehensive discussion of the key proteins required
for telomere replication and stability [69,75].
Owing to the requirement for DNA replication to begin
from an RNA primer, it is not possible to fully replicate the
lagging strand template at the very end of a chromosome
(known as the ‘end replication problem’). As a consequence,
telomeres shorten with each round of DNA replication in
somatic cells. In the absence of telomere maintenance mechan-
isms, cells can undergo a limited number of divisions before
they arrest in a state termed replicative senescence [76,77].
To avoid this fate, stem cells and germ cells use the telomerase
reverse transcriptase enzyme, which carries its own RNA as a
template for telomere extension [78–80]. Cancer cells also reac-
tivate telomere maintenance mechanisms to enable replicative
immortality [1]. Around 90% of human cancers activate
expression of telomerase [81], while the remaining 10% use a
process called ALT (the alternative lengthening of telomeres).
ALT appears to be more prevalent in those rare tumours of
mesenchymal origin, rather than the more common epithelial
cancers. ALT is a homologous recombination-mediated telo-
mere maintenance pathway [82–84]. The phenotypes of ALT
cells are the absence of telomerase, a heterogeneous telomere
length, the presence of a specialized PML body composed of
DNAdamage and repair proteins at telomeres (ALT-associated
PML bodies; APBs), an increased frequency of telomere sister
chromatid exchanges, and the presence of extra-chromosomal
telomeric DNA [85,86]. In addition, ALT cells frequently exhi-
bit loss of the ATRX protein and increased expression of
TERRA RNA [87–89]. ALT telomeres also appear to be sensi-
tive to DNA replication stress, as evidenced by an increased
propensity to exhibit fragility. This might be due to an elevated
level of TERRA transcription [90–92], as ALT cells are thought
to be more permissive for transcription due to an altered chro-
matin compaction [87]. Consistent with this, the depletion of
the two paralogues of the histone chaperone ASF1 (ASF1a
and ASF1b) induces ALT phenotypes, including increased
APBs and C-circles. Therefore, enhanced replication fork stal-
ling caused by dysfunctional histone dynamics might trigger
the induction of ALT at telomeres [93].
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Figure 1. Key steps involved in the BIR pathway. BIR initiates from a double
strand DNA end that has been resected to generate a 30 single stranded DNA
overhang (i). This overhang then invades into a homologous DNA duplex to
form D-loop (ii) followed by DNA synthesis and D-loop migration and sub-
sequent initiation of complementary strand synthesis (iii) [103].
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4An analogous mechanism to ALT is conserved in lower
eukaryotes. In the absence of telomerase in yeast, the rare
accumulation of so-called Type I and Type II survivors is
driven by the use of a homologous recombination-basedmech-
anism for telomere maintenance. The precise mechanism by
which these survivors arise is still not clear, but a recombina-
tion-driven process called break-induced replication (BIR) is
implicated in ALT in yeast, which will be discussed further
in the MiDAS section below [94]. Recent studies identified
two possible mechanisms for the ALT process in human
cells. When TRF1 was fused to a bacterial endonuclease FokI
(TRF1-FokI) in order to induce a DSB specifically at telomeres,
the resultant critically short or dysfunctional telomeres were
‘healed’ using either of two recombination-based telomere
maintenance pathways [95,96]. One of these putative ALT
mechanisms depends upon the major recombinase protein
RAD51, but the other does not. The RAD51-dependent
process, which requires a conventional homology search,
apparently uses the HOP2–MND1 heterodimer involved
in meiotic recombination [95]. By contrast, the RAD51-
independent process utilizes a pathway that was termed
‘break-induced telomere synthesis’. This process occurs out-
side of S-phase and requires POLD3, RFC1 and PCNA, but
not HOP2-MND1 [96].3. Mitotic DNA synthesis
Although the bulk of DNA replication is completed during
S-phase, it has been known for some time that certain regions
of the genome can show a delay in completion of DNA repli-
cation. While this was generally assumed to be occurring
during the G2 phase, recent data indicate that DNA synthesis
can still occur after the cells have initiated the prophase of
mitosis. In this section, we review the evidence that a form
of MiDAS occurs at CFSs and telomeres.
3.1. MiDAS at common fragile sites
The delayed replication of CFSs following DNA replication
stress was first reported almost two decades ago [33]. Indeed,
many studies have demonstrated that CFS replication can
sometimes occur outside of a conventional S-phase [51,97,98].
Recently, our laboratory demonstrated that DNA synthesis at
CFSs could be detected even after cells had entered the pro-
phase of mitosis [16]. Following the initiation of chromosome
condensation and the activation of the prophase pathway to
eliminate sister chromatid cohesion from chromosome arms,
any remaining under-replicated CFS loci trigger a non-canoni-
cal mode of mitotic DNA synthesis (which we termed
‘MiDAS’) [16]. Although this process is detectable in all cell
types, it is particularly prevalent in transformed cancer cell
lines that exhibit aneuploidy [16,99].
TheMiDAS pathway differs from conventional DNA repli-
cation in that it frequently uses a conservative form of DNA
synthesis. This was revealed by the distinctive patterns of nas-
cent DNA (labelled with EdU) on mitotic chromosomes [100].
In this respect, MiDAS resembles BIR in yeast, which uses a
conservative form of DNA synthesis [101,102] to repair
one-ended DSBs, such as those arising at broken/collapsed
replication forks. BIR may also be used to maintain ALT telo-
meres, as discussed above. BIR involves the invasion of the 30
single-stranded DNA overhang derived from a resected DSBinto a homologous double-stranded DNA, to form a D-loop
that allows the invading DNA to prime new DNA synthesis
(figure 1; reviewed in [103–105]). The first evidence for BIR
at difficult-to-replicate loci in human cells came from analysis
of oncogene-inducedDNA replication stress. A POLD3-depen-
dent form of BIRwas proposed as the pathway of choice for the
repair of the collapsed replication forks following cyclin E over-
expression [106]. Consistent with this, BIR in yeast requires
Pol32, the yeast homologue of POLD3 [107].
In addition to POLD3, MiDAS at CFSs in humans requires
the SLX4 scaffold protein, the MUS81-EME1 endonuclease,
and RAD52, but is RAD51-independent. Rather, the depletion
of RAD51 causes an increase in MiDAS, suggesting that
MiDAS is upregulated in the absence of RAD51. The require-
ment for RAD52, but not RAD51, is intriguing given that
most BIR in yeast requires Rad51, and the initiation of BIR is
believed to require a DNA strand invasion event that requires
Rad51. If MiDAS does occur via a BIR-like pathway, then this
suggests that, under specific circumstances, RAD52 can cata-
lyse an analogous reaction to strand invasion that permits
DNA synthesis to be primed. For example, MiDAS may be
a microhomology-mediated form of BIR (figure 2) [16,100].
Further reading on microhomology-mediated BIR can be
found in the following articles [104,105,108–110].
3.2. Mitotic DNA synthesis at telomeres
In addition toCFSs, events analogous toMiDAShave also been
observed at telomeres [91,99,111]. This telomeric MiDAS has
been characterized mainly in conjunction with the ALT
mechanism. For example, in a recent study, telomeric DSBs
in ALT cells were shown to be repaired by a conservative,
POLD3-dependent, form of telomere DNA synthesis. More-
over, this repair process did not require RAD51, making it
analogous to the MiDAS pathway at CFSs [96,112]. Surpris-
ingly, however, this process was not specific for cells using
the ALT mechanism, but was operational in all cell lines in
which a site-specific telomeric DSB was generated [96].
Hence, this form of so-called ‘break-induced telomere syn-
thesis’ might be a process that occurs only in the context of
the formation of a DSB within a telomere. Nevertheless,
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Figure 2. MiDAS at difficult-to-replicate loci. (a) Representative image of the detection of MiDAS in HeLa cells treated with low dose aphidicolin (APH). The ongoing
DNA synthesis marked by EdU incorporation (red) can be seen in relation to the telomeric DNA ends (green). DNA is stained with DAPI (blue). (b) A current model
for MiDAS [100]. The cartoon shows how a BIR-like process (figure 1) might occur at telomeres and CFSs when a stalled replication fork is broken and new DNA
synthesis is activated (red). The fact that the process is RAD51-independent (which is unusual for BIR) suggests that perhaps the annealing of the broken arm of the
fork occurs at a DNA structure that is already in an open conformation due to the presence of an R-loop or a DNA secondary structure.
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DNA secondary
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RAD51-dependent
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RAD51-independent
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Figure 3. The mechanisms for counteracting replication stress that prevent genome instability. Replication stress at difficult-to-replicate loci such as CFSs and tel-
omeres (indicated by stars on the chromosome arms) is initially dealt with via a canonical RAD51-dependent pathway before the cells enter into mitosis. When this
pathway fails, a non-canonical, RAD51-independent, process (MiDAS) takes over to prevent genomic instability. APH, aphidicolin, HU, hydroxyurea.
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5break-induced telomere synthesis is proposed to be analogous
to BIR in yeast cells that show an ALT-like telomere mainten-
ance system [113]. Indeed, recent work from the Shay group
identified a RAD51- and BRCA2-independent, but RAD52-
dependent, MiDAS pathway operating at ALT telomeres,which bears many of the hallmarks of BIR and CFS MiDAS
[91]. In another recent study, the loss of the Polh translesion
DNA polymerase was shown to induce telomeric MiDAS in
ALT cells [111]. Polh has been demonstrated previously to pro-
cess stalled replication forks at CFSs in S-phase in order to
mitotic aberrations
missegregation 53BP1 bodiesmicronuclei
chromatin
bridges
ultra-fine
bridges
lagging
chromatin
progression through
mitosis with unreplicated
DNA
next G1
PICH DAPI
53BP1 DAPI
exit from mitosis
locus1 locus2
DAPI
DAPI
DAPI
chromosome
gaps/breaks
DAPI
Figure 4. What happens when MiDAS fails? The consequences of MiDAS failure and progression through mitosis with unreplicated DNA could be not only the
formation of mitotic aberrations such as anaphase bridges, lagging chromatin and chromosome breaks/gaps, but also genomic instability in the next G1 cell cycle of
daughter cells. Mitotic anaphase bridges, which are classified as either chromatin bridges or ultra-fine bridges, are observed when cells attempt to segregate
incompletely replicated or unresolved DNA structures. This can lead to the daughter cells acquiring an incorrect chromosome number/structure, to the formation
of micronuclei, and to the formation of so-called 53BP1 nuclear bodies in the daughter G1 cells.
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6counteract fragile site instability [97]. This shared role for
Polh at CFSs and telomeres likely reveals a general mechanism
used by cells to counteract DNA replication stress at difficult-
to-replicate loci. Finally, there are contradictory findings
regarding the requirement for ATR in telomeric MiDAS.
The Shay group has shown that telomeric MiDAS is
ATR-dependent, while our group found that ATR inhibition
exacerbates telomeric MiDAS in a manner similar to that
seen with CFS-MiDAS [91,99]. The reason for this difference
is not known and requires further investigation.What is gener-
ally agreed is that the telomericMiDAS pathway uses a largely
conservative form of DNA synthesis that is analogous to BIR
in yeast. Telomeric MiDAS shares many features with CFS-
MiDAS, including a requirement for SLX4, RAD52 and
POLD3, but differs form CFS-MiDAS in being independent
of MUS81 (figure 2) [91,96,99].
In contrast to some of the studies reviewed above, our
characterization of the telomeric MiDAS pathway has shown
that telomeric MiDAS can be detected in most cell lines
exposed to aphidicolin, irrespective of their ALT status. We
also observed that the cells with the highest levels of basaltelomericMiDAS are thosewith the longest telomeres, particu-
larly if they use the ALT pathway. Nevertheless, we also
revealed a significant level of basal MiDAS in telomerase-posi-
tive cells that display a high degree of aneuploidy. Indeed,
although aphidicolin can activate telomeric MiDAS, the pres-
ence of aneuploidy seems to be a key factor in determining
whether the telomericMiDAS pathway is used in cells exposed
to DNA replication stress [99]. Our data indicate that telomeric
MiDAS is not synonymous with the ALT mechanism. Further-
more, it is known that several independent means of inducing
DNA replication stress, such as the overexpression of cyclin E,
treatment of cells with a G-quadruplex stabilizing ligand
(pyridostatin), and the depletion of RNase H1 to increase
R-loop formation, all increase telomeric MiDAS levels
[5,6,91,114,115]. Hence, we propose that MiDAS is a general
mechanism for counteracting DNA replication stress at any
form of difficult-to-replicate region of the genome, including
CFSs and telomeres. Further work will be required to assess
whether other difficult-to-replicate loci such as the rDNA
also depend on MiDAS for their stability following induction
of DNA replication stress.
Table 1. The list of proteins implicated thus far in MiDAS, by either promoting or suppressing MiDAS at CFS and/or telomeres. SCEs, sister chromatid exchanges;
TIFs, telomere induced foci.
proteins implicated role in MiDAS consequences in the absence of the protein references
ERCC1 localized to EdU incorporation in G2/M
at CFSs
increased chromatin bridges, chromosome segregation failures,
mitotic catastropy, CFS fragility/expression, 53BP1 bodies
[51]
SLX4 required for CFS- and telomeric MiDAS decreased CFS expression, increased UFBs, chromatin bridges,
53BP1 bodies
[16,99]
MUS81 required for CFS-MiDAS, but not for
telomeric MiDAS
increased chromatin bridges, chromosome segregation failures,
mitotic catastropy, 53BP1 bodies, decreased CFS expression
[16,51,99]
EME1 required for CFS-MiDAS not addressed [16]
WAPL required for CFS- and telomeric MiDAS decreased CFS expression, increased UFBs, chromatin bridges,
53BP1 bodies
[16]
SMC2 required for CFS- and telomeric MiDAS decreased CFS expression, increased UFBs, chromatin bridges,
53BP1 bodies
[16]
replicative
polymerases
required for CFS- and telomeric MiDAS increased 53BP1 bodies, non-disjunction, binucleation [16,99]
POLD3 required for CFS-MiDAS and break-
induced telomere synthesis
decreased CFS expression, increased 53BP1 bodies, UFBs,
decreased telomere length, increased TIFs, decreased c-circles
[16,96,112]
PLK required for CFS-MiDAS not addressed [16]
TOPBP1 required for MiDAS at CFSs increased 53BP1 bodies, binucleation [98]
RAD52 required for CFS- and telomeric MiDAS increased 53BP1, chromatin bridges, UFBs, micronuclei,
decreased CFS expression
[91,99,100]
PCNA required for break-induced telomere
synthesis
not addressed [96]
RFC required for break-induced telomere
synthesis
not addressed [96]
Smc5/6 complex required for telomeric MiDAS decreased telomere clustering [91]
RECQ5 required for CFS-MiDAS decreased CFS expression, increased chromatin bridges, UFBs,
micronuclei, 53BP1 bodies
[120]
MRE11 required for telomeric MiDAS not addressed [91]
Pol h suppresses G2/M DNA synthesis at CFSs
and telomeric MiDAS (not a mitosis
speciﬁc protocol)
increased 53BP1 bodies, SCEs at CFSs and increased APBs,
c-circles, t-SCEs, telomere fragility
[97,111]
ATR suppresses CFS-MiDAS, contradicting
reports on telomeric MiDAS
increased CFS expression [91,96,99,100]
RAD51 suppresses CFS- and telomeric MiDAS increased telomere fragility, increased TIFs [91,96,100]
BRCA2 suppresses CFS- and telomeric MiDAS increased telomere fragility, increased TIFs [91,100]
HOP2 suppresses telomeric MiDAS not addressed [96]
TIMELESS/TIPIN
complex
suppresses telomeric MiDAS increased telomere clustering [91]
rsob.royalsocietypublishing.org
Open
Biol.8:180018
7ALT cells appear to exhibit higher levels of DNA replication
stress and telomeric fragility than telomerase-positive cells
[90–92]. An increase in the frequency of replication–transcrip-
tion collisions (generating R-loops) and/or the possibility that
the longer telomeres in ALT cells are more prone to form repli-
some-blocking G-quadruplexes might explain the higher basal
levels of telomeric MiDAS observed in ALT cell lines. One
speculative mechanism that ALT cells might use to minimize
telomere instability is to co-opt the TERRA RNA for activating
DNA synthesis. Consistent with this, TERRA-dependent R-loops, rather than being pathological, might promote telomere
maintenance inALT cells, as evidenced by telomere shortening
upon RNase H1 overexpression [90].4. What happens when MiDAS fails?
Our contention is that, in order to counteract replication stress,
transformed/cancer cells use a RAD51-dependent homolo-
gous recombination repair pathway in late S/G2 to try to
rsob.royalsocietypublishing.org
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8effect the completion of replication. If this fails for any reason,
and cells enter mitosis with unreplicated DNA, they then
switch to the RAD52-dependent MiDAS pathway. MiDAS at
both CFSs and telomeres seems to constitute a final attempt
(analogous to a salvage pathway) to complete DNA synthesis
and hence to prevent extensive genomic instability (figure 3).
Indeed, under-replicated regions, or unresolved DNA struc-
tures, can lead to mitotic aberrations such as chromatin
bridges, UFBs, lagging chromatin and chromosome gaps and
breaks. Furthermore, they can also generate micronuclei and
53BP1 bodies in the subsequent G1 phase (figure 4) [116–
119]. MiDAS is, therefore, important for suppressing these
abnormalities by counteracting the high levels of DNA replica-
tion stress arising at difficult-to-replicate loci. Consistent with
this, depletion of key MiDAS factors (e.g. RAD52), or acute
inhibition of MiDAS by exposure to a high dose of aphidicolin
in mitosis, have been shown to directly induce mitotic aberra-
tions and chromosome missegregation [16,100].5. MiDAS inhibitors for cancer therapy?
The elevated levels of MiDAS observed in cancer cells make
this pathway a feasible target for anti-cancer therapy [16,99].
Indeed, a reliance on MiDAS might allow cancer cells to
better tolerate the chronic DNA replication stress associated
with oncogene activation. Identifying the key players of
MiDAS (table 1) will enable the development of strategies to
target this pathway [16,51,91,96–100,111,112,120]. Potentiation
of DNA replication stress to toxic levels by inhibiting the ATR
kinase is a strategy being used to target the chronic DNA repli-
cation stress phenotype of cancer cells, and this would be
expected to make ATR-deficient cancer cells even more reliant
on MiDAS for survival. In this scenario, we propose that ATR
inhibitors and MiDAS inhibitors could be an effective combi-
natorial strategy to trigger irreparable DNA replication stress
in cells with activated oncogenes. Indeed, as a proof-of-
principle, we have demonstrated that RAD52 inhibition
potentiates the effects of an ATR inhibitor in cancer cells [100].6. Concluding remarks
Recent studies have expandedour understanding of theMiDAS
pathway and the consequences of DNA replication stress at dif-
ficult-to-replicate loci. However, several questions still remain
unanswered. For example, the predominant MiDAS pattern
wherebyEdU incorporation is seen ononlyone sister chromatid
at CFSs and telomeres seems to be a signature of the conserva-
tive BIR pathway [91,99,100,112]. However, EdU incorporation
also occurs on both sister chromatids in 20%–40% of the cases,
and sometimes shows variegated signals. It is possible, there-
fore, that different sub-pathways of MiDAS are deployed atdifferent types of DNA structures. For example, fork cleavage
may create a one-ended DSB for BIR, whereas under-replicated
regions may be unwound to generate two ssDNA gaps that are
repaired via othermeans. To better understand these processes,
it will be of interest to identify any conditions that alter the pat-
tern of EdU incorporation in mitosis. Furthermore, the
molecular mechanisms of MiDAS could be characterized
further through the use of site-specific DNA replication barriers
which could be used to create defined regions of the genome
that are maintained exclusively by MiDAS.
The current model of MiDAS is analogous to the RAD51-
independent BIR mechanism in yeast [100]. Nevertheless, it
appears that RAD51-dependent repair occurs during the late
S/G2 phases in an attempt to complete DNA synthesis
before mitosis, implying that RAD51-independent MiDAS
only occurs in mitosis as a back-up ‘salvage’ pathway
[95,96,100]. It will be interesting to test how both types
(RAD51-dependent or independent) of BIR cooperate in
human cells to repair stalled replication forks at difficult-to-
replicate loci, and how their relative usage is regulated by the
level of DNA replication stress and the stage of the cell cycle.
One critical deficiency in our knowledge concerns the
nature of the lesion(s) that cause replication fork stalling at
CFSs and telomeres in the first place. Indeed, perhaps there is
no single form of ‘roadblock’ implicated in this, and therefore
it does not matter how the replisome is disrupted because
the end result is always the same; the replication fork will
need to be rescued. Recent work has provided some evidence
for this contention, in that the stabilization of either G-quadru-
plexes or R-loops has been shown to increase the dependence
on telomeric MiDAS [91]. Finally, further work is required to
improve our understanding of the putative role of RNA species
(TERRA or R-loops) in MiDAS, and to determine their
physiological (as well as potentially pathological) roles at
these regions [121,122]. It is intriguing that various types of
RNA species appear to play prominent roles that likely
determine CFS and telomere stability. Of note, it remains
unknown as to why many of the transcripts generated at
CFSs are so large. Although R-loops are conventionally
considered as pathological, increasing evidence suggests that
these RNA : DNA hybrids might have important physiological
roles under some circumstances.Data accessibility. This article has no additional data.
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